Study S002340

A Multicenter, Randomized, Double Blind (Double Dummy), Active Controlled Study to Compare the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Pioglitazone in Type 2 Diabetes Patients Inadequately Controlled on Therapy With Sulfonylurea or Metformin Plus Sulfonylurea

ClinicalTrials.gov record

Registration

Registration: NCT00909597
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 756
Start: 2009-05
Primary completion: 2010-11
Lead sponsor: Hoffmann-La Roche
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:pioglitazone; DRUG:taspoglutide
Results posted: FALSE
Secondary identifiers: OTHER:2009-009157-24; NIH:2009

Registered primary outcomes

Absolute change from baseline in HbA1c [24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.